PharmacoEconomics

Economic and Human Costs of Restless Legs Syndrome
pp. 267-279(13)
Authors: Reinhold, Thomas; Müller-Riemenschneider, Falk; Willich, Stefan N.; Brüggenjürgen, Bernd

Reviewing the Cost Effectiveness of Rotavirus Vaccination: The Importance of Uncertainty in the Choice of Data Sources
pp. 281-297(17)
Authors: Bilcke, Joke; Beutels, Philippe

Willingness to Pay for Cancer Prevention
pp. 299-312(14)
Authors: Hunt, Timothy L.; Luce, Bryan R.; Page, Matthew J.; Pokrzywinski, Robin

Cost Effectiveness of Drug-Eluting Stents In Belgian Practice: Healthcare Payer Perspective
pp. 313-327(15)
Authors: Neyt, Mattias; >Chris De Laet,; >Annemieke De Ridder,; >Hans Van Brabandt,

Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder: Results from the MATRIX Study
pp. 329-339(11)
Authors: Pizzi, Laura T.; Talati, Amy; Gemmen, Eric; Dahl, Naomi V.; Bunz, Thomas J.; Sand, Peter K.

Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response: A Decision Analysis Based on German Guidelines
pp. 341-354(14)
Authors: Siebert, Uwe; Sroczynski, Gaby; Aidelsburger, Pamela; Rossol, Siegbert; Wasem, Jürgen; Manns, Michael P.; McHutchison, John G.; Wong, John B.